By Adria Calatayud

AstraZeneca PLC (AZN.LN) said Monday that the results of a phase 3 clinical trial for its Imfinzi antibody will be delayed until the second half of the year.

The pharmaceutical company said it had previously expected to release the results of the clinical trial in the first half. It didn't provide details on the cause of the delay.

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

(END) Dow Jones Newswires

March 12, 2018 03:27 ET (07:27 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.